AR098830A2 - Suspensiones acuosas estabilizadas para administración parenteral - Google Patents

Suspensiones acuosas estabilizadas para administración parenteral

Info

Publication number
AR098830A2
AR098830A2 ARP140104760A ARP140104760A AR098830A2 AR 098830 A2 AR098830 A2 AR 098830A2 AR P140104760 A ARP140104760 A AR P140104760A AR P140104760 A ARP140104760 A AR P140104760A AR 098830 A2 AR098830 A2 AR 098830A2
Authority
AR
Argentina
Prior art keywords
parenteral administration
biologically active
methionine
active compound
compound
Prior art date
Application number
ARP140104760A
Other languages
English (en)
Original Assignee
Pfizer Italia Srl
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Italia Srl, Pharmacia & Upjohn Spa filed Critical Pfizer Italia Srl
Publication of AR098830A2 publication Critical patent/AR098830A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Abstract

Una formulación en suspensión acuosa farmacéutica para su administración parenteral que tiene un pH sustancialmente estabilizado, que comprende un compuesto biológicamente activo y una concentración efectiva de control del pH de L-metionina. Uso de L-metionina en la preparación de una formulación en suspensión acuosa farmacéutica que tiene un pH sustancialmente estabilizado, para la administración parenteral de un compuesto biológicamente activo, y de L-metionina y un agente de buffer en concentraciones efectivas como para producir un efecto súper-aditivo de control del pH. Reivindicación 7: Una composición farmacéutica de acuerdo con la reivindicación 6,caracterizada porque el compuesto biológicamente activo es un compuesto esteroidal. Reivindicación 8: Una composición farmacéutica de acuerdo con la reivindicación 7, caracterizada porque el compuesto esteroidal biológicamente activo se selecciona entre exemestano, medroxi-progesterona-acetato y estradiol-cipionato o una mezcla de medroxi-progesterona-acetato y estradiol-cipionato.
ARP140104760A 2000-05-15 2014-12-18 Suspensiones acuosas estabilizadas para administración parenteral AR098830A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/571,395 US6495534B2 (en) 2000-05-15 2000-05-15 Stabilized aqueous suspensions for parenteral use

Publications (1)

Publication Number Publication Date
AR098830A2 true AR098830A2 (es) 2016-06-15

Family

ID=24283530

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP010102268A AR029924A1 (es) 2000-05-15 2001-05-14 Suspensiones acuosas estabilizadas para administracion parenteral
ARP140104760A AR098830A2 (es) 2000-05-15 2014-12-18 Suspensiones acuosas estabilizadas para administración parenteral
ARP180101264A AR111695A2 (es) 2000-05-15 2018-05-14 Suspensiones acuosas estabilizadas para administración parenteral

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP010102268A AR029924A1 (es) 2000-05-15 2001-05-14 Suspensiones acuosas estabilizadas para administracion parenteral

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP180101264A AR111695A2 (es) 2000-05-15 2018-05-14 Suspensiones acuosas estabilizadas para administración parenteral

Country Status (30)

Country Link
US (3) US6495534B2 (es)
EP (1) EP1282402B1 (es)
JP (1) JP4205341B2 (es)
KR (1) KR100828957B1 (es)
CN (1) CN100473376C (es)
AR (3) AR029924A1 (es)
AT (1) ATE313316T1 (es)
AU (2) AU2001267371B2 (es)
BR (1) BR0110841A (es)
CA (1) CA2409059C (es)
CZ (1) CZ303872B6 (es)
DE (1) DE60116084T2 (es)
DK (1) DK1282402T3 (es)
EA (1) EA007682B1 (es)
EE (1) EE05376B1 (es)
ES (1) ES2254443T3 (es)
HK (1) HK1054194B (es)
HU (1) HU229800B1 (es)
IL (2) IL152537A (es)
IN (1) IN224279B (es)
MX (1) MXPA02011195A (es)
NO (1) NO332215B1 (es)
NZ (1) NZ522324A (es)
PE (1) PE20011322A1 (es)
PL (1) PL203075B1 (es)
SI (1) SI1282402T1 (es)
SK (1) SK287641B6 (es)
TW (1) TWI256310B (es)
WO (1) WO2001087266A1 (es)
ZA (1) ZA200208738B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
US7482116B2 (en) 2002-06-07 2009-01-27 Dna Genotek Inc. Compositions and methods for obtaining nucleic acids from sputum
AU2003265511A1 (en) 2002-08-21 2004-03-11 Pharmacia Corporation Injectable pharmaceutical suspension in a two-chamber vial
EP1560577A2 (en) * 2002-11-08 2005-08-10 Bristol-Myers Squibb Company Pharmaceutical compositions and methods of using taxane derivatives
KR20060002922A (ko) * 2003-03-31 2006-01-09 알자 코포레이션 비수성 단일 상 비히클 및 이러한 비히클을 이용한 제형
BRPI0413200A (pt) 2003-09-03 2006-10-03 Miscon Trading S A método para tratamento de endometriose
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US20060058390A1 (en) * 2004-09-14 2006-03-16 Molecular Therapeutics, Inc. D-methionine formulation with improved biopharmaceutical properties
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
US20070191323A1 (en) * 2006-02-15 2007-08-16 Verus Pharmaceuticals, Inc. Stable corticosteroid mixtures
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
JP5371180B2 (ja) * 2006-06-15 2013-12-18 日立コンシューマエレクトロニクス株式会社 投写型映像表示装置
US7589106B2 (en) * 2006-09-27 2009-09-15 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
US7687516B2 (en) * 2006-09-27 2010-03-30 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
US20100076019A1 (en) * 2006-10-11 2010-03-25 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
GB0625962D0 (en) * 2006-12-23 2007-02-07 Renovo Ltd Medicaments and methods for wound healing
EP2185112A4 (en) * 2007-08-21 2012-01-18 Harbor Biosciences Inc STABILIZED THERAPEUTIC COMPOSITIONS AND FORMULATIONS
US8287729B2 (en) * 2008-04-28 2012-10-16 California Polytechnic Corporation Field water purification system
GB0813628D0 (en) * 2008-07-25 2008-09-03 Arrow Int Ltd Stable coated anti-cancer agent
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
AU2012273121B2 (en) 2011-06-19 2016-08-25 Abogen, Inc. Devices, solutions and methods for sample collection
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
UA74095U (ru) * 2012-07-20 2012-10-10 Николай Иванович Гуменюк Препарат для лечения туберкулеза
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9649353B2 (en) 2013-09-17 2017-05-16 Terapio Corporation Methods of preventing or treating mucositis by administering RLIP76
CN104706578B (zh) * 2013-12-14 2019-04-23 天津金耀集团有限公司 一种醋酸甲泼尼龙混悬注射液组合物的制备方法
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US11135154B2 (en) 2016-03-02 2021-10-05 Teva Pharmaceutical Industries Ltd. Medroxyprogesterone acetate injectable compositions and methods of use
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11590077B2 (en) * 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
MX2018013414A (es) * 2016-05-06 2019-06-06 Eagle Pharmaceuticals Inc Formulaciones de fulvestrant y metodos para su uso.
WO2019049081A1 (en) * 2017-09-07 2019-03-14 Teva Pharmaceutical Industries Ltd. INJECTABLE COMPOSITIONS OF MEDROXYPROGESTERONE ACETATE AND METHODS OF USE
EP3678637A1 (en) * 2017-09-07 2020-07-15 Teva Pharmaceutical Industries Ltd. Medroxyprogesterone acetate injectable compositions and methods of use
MA50570A (fr) * 2017-11-08 2020-09-16 Eagle Pharmaceuticals Inc Formulations de fulvestrant et méthodes d'utilisation de ces dernières
KR20200108023A (ko) * 2018-01-11 2020-09-16 메리테이지 파마, 인크. 안정한 코르티코스테로이드 조성물
US11752095B2 (en) 2018-09-07 2023-09-12 Family Health International Medroxyprogesterone acetate injectable compositions and methods of use
US10544923B1 (en) 2018-11-06 2020-01-28 Verifone, Inc. Devices and methods for optical-based tamper detection using variable light characteristics
WO2020106891A1 (en) 2018-11-20 2020-05-28 Spectrum Solutions, Llc Sample collection system including sealing cap and valve
IT201900002857A1 (it) * 2019-02-27 2020-08-27 Ntc S R L Procedimento di riempimento di contenitori con una polvere
US11701094B2 (en) 2019-06-20 2023-07-18 Spectrum Solutions L.L.C. Sample collection system including valve and plug assemblies
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
WO2022245939A1 (en) * 2021-05-19 2022-11-24 Acies Medical Llc Point-of-use calibration system for iron ion detection system

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) * 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
US4038389A (en) * 1975-05-07 1977-07-26 The Upjohn Company Medroxyprogesterone acetate compositions
US4154820A (en) * 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
JP2577744B2 (ja) 1986-07-18 1997-02-05 中外製薬株式会社 安定な顆粒球コロニ−刺激因子含有製剤
US5208261A (en) * 1989-12-06 1993-05-04 Akzo N.V. Stabilized solutions of psychotropic agents
ES2062310T3 (es) * 1989-12-06 1994-12-16 Akzo Nv Un procedimiento para fabricar un preparado farmaceutico acuoso estabilizado.
JPH0597671A (ja) 1991-10-04 1993-04-20 Sumitomo Pharmaceut Co Ltd 注射用凍結乾燥製剤
CA2120197A1 (en) 1993-04-02 1994-10-03 Kenji Endo Stable aqueous dispersions containing liposomes
JP3862295B2 (ja) * 1993-09-30 2006-12-27 独立行政法人理化学研究所 抗肥満剤
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
JP3543144B2 (ja) 1995-03-11 2004-07-14 国際試薬株式会社 臨床検査用製剤
US5780431A (en) 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
CN1142940C (zh) 1996-10-04 2004-03-24 安姆根有限公司 含有mpl配体的药物组合物
US5773432A (en) * 1996-10-30 1998-06-30 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
US5880116A (en) * 1996-12-13 1999-03-09 Neurocal International Use of celastrol to treat alzheimer's disease
JP3748970B2 (ja) 1997-01-31 2006-02-22 電気化学工業株式会社 ヒアルロン酸ナトリウム含有水溶液
KR100508227B1 (ko) 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
DE59811910D1 (de) * 1997-09-23 2004-10-07 Rentschler Biotech Gmbh Flüssige Interferon-Beta Formulierungen
US5968918A (en) * 1997-10-17 1999-10-19 Kanda; Iwao Method for the prevention of coronary artery spasm
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
AU747975B2 (en) 1998-04-02 2002-05-30 N.V. Organon Oral liquid antidepressant solution
CZ20021186A3 (cs) 1999-10-04 2002-11-13 Chiron Corporation Farmaceutické prostředky obsahující stabilizovaný kapalný polypeptid
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use

Also Published As

Publication number Publication date
EE05376B1 (et) 2011-02-15
PL203075B1 (pl) 2009-08-31
SK15982002A3 (sk) 2003-05-02
MXPA02011195A (es) 2003-03-10
WO2001087266A1 (en) 2001-11-22
NO332215B1 (no) 2012-07-30
DE60116084T2 (de) 2006-08-17
JP4205341B2 (ja) 2009-01-07
AU2001267371B2 (en) 2006-01-05
HUP0302021A2 (hu) 2003-09-29
HUP0302021A3 (en) 2011-03-28
NZ522324A (en) 2005-02-25
EA200201208A1 (ru) 2003-04-24
NO20025431D0 (no) 2002-11-13
CZ20023750A3 (cs) 2003-03-12
AR029924A1 (es) 2003-07-23
NO20025431L (no) 2003-01-13
EP1282402B1 (en) 2005-12-21
DK1282402T3 (da) 2006-05-08
AU6737101A (en) 2001-11-26
IL165888A0 (en) 2006-01-15
JP2003533467A (ja) 2003-11-11
PE20011322A1 (es) 2002-01-10
SK287641B6 (sk) 2011-05-06
IN224279B (es) 2005-02-25
KR100828957B1 (ko) 2008-05-13
ATE313316T1 (de) 2006-01-15
PL365793A1 (en) 2005-01-10
KR20030020280A (ko) 2003-03-08
US20020115645A1 (en) 2002-08-22
EP1282402A1 (en) 2003-02-12
AR111695A2 (es) 2019-08-07
US20030114430A1 (en) 2003-06-19
SI1282402T1 (sl) 2006-04-30
IL152537A (en) 2007-06-17
EA007682B1 (ru) 2006-12-29
CZ303872B6 (cs) 2013-06-05
CN1429101A (zh) 2003-07-09
HU229800B1 (en) 2014-07-28
ZA200208738B (en) 2003-10-29
HK1054194B (zh) 2010-02-12
IL152537A0 (en) 2003-05-29
ES2254443T3 (es) 2006-06-16
BR0110841A (pt) 2003-03-11
EE200200631A (et) 2004-04-15
CA2409059A1 (en) 2001-11-22
TWI256310B (en) 2006-06-11
CA2409059C (en) 2006-04-18
HK1054194A1 (en) 2003-11-21
DE60116084D1 (de) 2006-01-26
US20030130245A1 (en) 2003-07-10
CN100473376C (zh) 2009-04-01
US6495534B2 (en) 2002-12-17

Similar Documents

Publication Publication Date Title
AR098830A2 (es) Suspensiones acuosas estabilizadas para administración parenteral
CO5700797A2 (es) Composicion de farmaco conjugado
AR052545A1 (es) Suspension no acuosa inyectable
PE20070437A1 (es) FORMULACION ACUOSA hFSH
UA99815C2 (ru) Лиофилизированная композиция терапевтического пептидного антитела
PE20130589A1 (es) Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a
PE20131324A1 (es) Formulacion subcutanea de anticuerpo anti-her2
NZ593190A (en) Factor viii formulations
AR067011A1 (es) Formulaciones de anticuerpos
ATE464880T1 (de) Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator
HUP0301405A2 (hu) Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
MY197773A (en) Highly concentrated pharmaceutical formulations comprising anti-cd20 antibody
AR049063A1 (es) Composiciones farmaceuticas inyectables de posaconazol con particulas estabilizadas
CO5271759A1 (es) Formulacion en solucion que contiene una mezcla de disolventes
RS53548B1 (en) THERAPEUTIC FORMULATIONS OF KERATINocyte GROWTH FACTORS
AR006308A1 (es) Sistema dispensador; un metodo para estabilizar una composicion; una composicion acuosa y el uso del sistema dispensador.
BRPI0510684A (pt) composições para adiministração tópica ou transdérmica de agente anticolinérgico ou antiespasmódico e uso dos respectivos compostos
AR024634A1 (es) Composicion farmaceutica estabilizada en forma liofilizada
BRPI0413957A (pt) processo para preparar diterpenos solúveis em água, solução aquosa e suas aplicações
PE20110302A1 (es) Formulacion farmaceutica de un anticuerpo contra p-selectina
PE63998A1 (es) Composiciones anti-fungosas
ATE202931T1 (de) Taxanderivate enthaltende arzneizubereitungen
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
DE60221227D1 (de) Xanthangummi enthaltende reepithelialisierende pharmazeutische Zubereitungen

Legal Events

Date Code Title Description
FB Suspension of granting procedure